Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 15;4(5):426-34.
eCollection 2014.

The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature

Alireza Mojtahedi  1 , Sanjay Thamake  2 , Izabela Tworowska  2 , David Ranganathan  3 , Ebrahim S Delpassand  1
Affiliations
Review

The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature

Alireza Mojtahedi et al. Am J Nucl Med Mol Imaging. .

Abstract

Neuroendocrine tumors (NETs) are rare group of neoplasms arising from nervous and endocrine systems. Somatostatin analogue imaging is a functional imaging modality of choice for evaluating the NETs. Recent availability of positron emitting radioisotope labeled somatostatin analogues to image neuroendocrine cancers, has raised the interests to use this new imaging modality in management of patients with NETs. (68)Ga-DOTATATE PET/CT has demonstrated superiority in lesion detection compared to Octreoscan, MIBG scintigraphy and MRI. In this article, we reviewed the published studies evaluating the role of (68)Ga-DOTATATE PET in diagnosis and management of patients with neuroendocrine tumors and comparing it to current FDA approved imaging modalities including Octreoscan, MIBG scintigraphy, (18)F FDG PET/CT, CT and MRI.

Keywords: DOTATATE; Gallium 68; hybrid imaging; neuroendocrine tumors; positron emission tomography.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Side by side comparison of 68Ga-DOTATATE to Octreoscan from one of our patients with neuroendocrine tumor. Anterior (A) and posterior (B) 68Ga-DOTATATE pet images demonstrate extensive metastatic disease. Octreoscan anterior (C) and posterior (D) images from same patient demonstrate much fewer lesions indicating superior quality of PET/CT imaging
See this image and copyright information in PMC

References

    1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. - PubMed
    1. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323:1246–9. - PubMed
    1. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–4. - PubMed
    1. Chopra A. 99mTc-ethylenediamine N,N’-diacetic acid/hydrazinonicotinamide-Tyr3-octreotide. In: Chopra A, editor. Molecular Imaging and Contrast Agent Database (MICAD) Bethesda: NIH; 2007.
    1. Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D. What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging. 2007;34:1897–1901. - PubMed

LinkOut - more resources